Positively Stupid! Barnett Tests Positive for Anabolic Steroid

Written by Tom Ngo
July 22nd, 2009

Josh Barnett <a href=Affliction: Banned Post-Fight Press Conference” width=”350″ height=”250″ />

The California State Athletic Commission is reporting that traces of metabolite (2a-methyl-5a-androstan- 3a-ol-17-one), of the anabolic steroid Drostanolone, were found in heavyweight Josh Barnett’s system when he submitted an “Affliction: Trilogy” pre-fight test on June 25th.

“The license of Josh Barnett was denied pursuant to rule 303 of Title IV of the California Code of Regulations,” CSAC Interim Executive Officer Dave Thornton stated. “That rule prohibits the use of certain substances, including anabolic agents, by any boxer or MMA fighter.

“Our primary concern is for the health and safety of fighters. Anabolic agents and other banned substances put the users of those agents at risk, as well as their opponents. The commission simply will not tolerate their use.”

This isn’t Barnett’s first interaction with roids as he was suspended for six months by the Nevada State Athletic Commission in 2002 after a post-fight urinalysis revealed the presence of three anabolic agents (Boldenone metabolite, Fluoxymesterone metabolite and Nandrolone metabolite) in his body when he defeated Randy Couture to capture the UFC crown.

Barnett denied using the anabolic steroids and challenged the NSAC’s testing protocol back then and has already started the appeals process with the CSAC.

With Barnett’s abrupt exit from “Affliction: Trilogy,” the organization has less than 10 days to find an opponent for WAMMA heavyweight champ Fedor Emelianenko.

On today’s conference call, company vice president Tom Atencio stated that he is leaving no stone unturned in his attempt to find an opponent “worthy” of facing the Russian in the night’s main event.

Still no word on who Affliction is going to lock in, but it appears that former UFC light heavyweight champion Vitor Belfort is the early front-runner.

Don’t forget to follow @5thRound on Twitter, Facebook and Google+!